Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing
Based on separate protective mechanisms related to lipid metabolism, viral cell entry and inflammation, fibrate treatment might be advantageous among patients who have been taking fibrates before SARS-CoV-2 infection and continue taking them during the infection. Based on published data on hospitali...
Main Authors: | Alpo Vuorio, Jonas Brinck, Petri T. Kovanen |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | Annals of Medicine |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2022.2095667 |
Similar Items
-
Digital <i>h</i>-Fibrations and Some New Results on Digital Fibrations
by: Talip Can Termen, et al.
Published: (2024-03-01) -
Effect of Lipids on Diabetic Retinopathy in a Large Cohort of Diabetic Patients after 10 Years of Follow-Up
by: Pedro Romero-Aroca, et al.
Published: (2023-10-01) -
Association between Chronic Periodontitis and Serum Lipid Levels with its Risk to Atherosclerosis
by: Kush Pathak, et al.
Published: (2014-01-01) -
Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort
by: Meral Kayıkçıoğlu, et al.
Published: (2020-06-01) -
SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease
by: Petri T. Kovanen, et al.
Published: (2023-09-01)